Loading...
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Attempts to improve upon the activity of ibrutinib in chronic lymphocytic leukemia (CLL) include the addition of targeted therapies. The combination of lenalidomide and rituximab demonstrated an overall response rate (ORR) of 66% with a complete response (CR) of 12% in the relapsed/refractory settin...
Na minha lista:
| Udgivet i: | Blood Adv |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5894261/ https://ncbi.nlm.nih.gov/pubmed/29610115 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017015263 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|